Biocept Inc (NASDAQ: BIOC), the provider of molecular diagnostic and services, has announced that the company, for its Primer-Switch technology, has been awarded South Korean Patent.
Fourth Issued Patent: As per the company, with the inclusive of South Korean Patent, the total patent count increases to fourth for the Primer-Switch technology. The technology helps detect rare mutations in ctDNA (circulating tumor DNA) using real-time PCR and analysis associated with the method. This patent is titled “Methods for Detecting Nucleic Acid Sequence Variants.”
Primer – Switch technology provides a different method to specialists for enriching patient samples for mutation of interest. One can use the technology to increase the performance and specification of the PCR method. Moreover, it enables the interrogation of fragmented DNA, which is usually found in biological fluids.
New Technology supplements Switch – Blocker Technology: Primer – Switch methodology supplements the earlier developed technology (Switch – Blocker). It provides vital information on cancer biomarkers which help the specialist (physician) in decision making. In addition, the company increasing intellectual offering portfolio and enables Biocept to develop more innovative technology in the time to come. Over 70 patents protect Biocept technology in the U.S, Australia, E.U. China, South Korea, and Japan. It also includes global patent protection on a critical sensitive method for detecting cancer biomarkers that the specialist uses for the treatment.
The company is also working on its diagnostic capabilities to offer the nation RT – PCR – based COVID 19 testing to support public health. In addition, the company continues research and development to enhance its product portfolio and develop innovative technology in the medical and pharmaceutical industry, which can help the physician decide and provide actionable information to diagnose treatment and monitor the patient’s progress.